Genentech Restricts Population In Last-Ditch Bid To Keep Avastin's Breast Cancer Claim
This article was originally published in The Pink Sheet Daily
Executive Summary
Final submission from Genentech focuses on revised indication and Risk Evaluation and Mitigation Strategy to support continued approval while it conducts another confirmatory trial.
You may also be interested in...
Perjeta, Avastin Breast Cancer Approvals Are A Study In Contrasts
Pertuzumab’s approval came almost a year after FDA and Genentech battled over the future of bevacizumab’s breast cancer claim at an unprecedented public hearing. While both oncologic agents were approved on the basis of a median progression-free survival benefit exceeding five months, the regulatory similarities end there.
Oncology Drug Applications Migrate As Part Of FDA's Reorganization Of OODP
Many NDAs, BLAs and INDs for cancer drugs are being reassigned to new review divisions as part of a reorganization of FDA’s Office of Oncology Drug Products.
Oncology Drug Applications Migrate As Part Of FDA's Reorganization Of OODP
Many NDAs, BLAs and INDs for cancer drugs are being reassigned to new review divisions as part of a reorganization of FDA’s Office of Oncology Drug Products.